This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors
Having signed the written Informed Consent Form (ICF);
Male or female aged ≥18 years;
Life expectancy ≥12 weeks;
Eastern Cooperative Oncology Group (ECOG) Performance Score 0 or 1;
Previous or current use of POLQ inhibitors;
Hypersensitivity to the active pharmaceutical ingredient or any excipient of SYN818;
Central nervous system (CNS) metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that CNS metastasis or meningeal metastasis has not been adequately controlled;
Other malignant tumors than the study tumors within 5 years prior to the first dose of the study drug, except for localized cancers that have been evidently cured or disease-free for at least 3 years, such as basal or squamous cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, carcinoma in situ of cervix, or carcinoma in situ of breast;